João Casaca-Carreira

João Casaca-Carreira

Auto-generated profile, based on publicly available information

João Casaca-Carreira

Department of Neurosurgery, Maastricht University Medical Center , Maastricht, the Netherlands

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Nucleic Acid Therapeutics
Verified
Journal Article
Open access
LTLodewijk J.A. Toonen
Lodewijk J.A. Toonen
JCJoão Casaca-Carreira
João Casaca-Carreira
MPMaria Pellisé-Tintoré
Maria Pellisé-Tintoré
HMHailiang Mei
Hailiang Mei
Yasin TemelYasin Temel
Yasin Temel
WRWilleke M.C. van Roon-Mom
Willeke M.C. van Roon-Mom
Antisense oligonucleotides (AONs) are versatile molecules that can be used to modulate gene expression by binding to RNA. The therapeutic potential of AONs appears particularly high in the central nervous system, due to excellent distribution and uptake in brain cells, as well as good tolerability in clinical trials thus far. Nonetheless, immune stimulation in response to AON treatment in the brain remains a concern. For this reason we performed RNA sequencing analysis of brain tissue from mice treated intracerebroventricularly with phosphorothioate, 2′-O-methyl modified AONs. A significant upregulation of immune system associated genes was observed in brains of AON treated mice, with the striatum showing largest transcriptional changes. Strongest upregulation was seen for the antiviral enzyme 2′-5′-oligoadenylate synthase-like protein 2 (Oasl2) and Bone marrow stromal antigen 2 (Bst2). Histological analysis confirmed activation of microglia and astrocytes in striatum. The upregulation of immune system associated genes was detectable for at least 2 months after the last AON administration, consistent with a continuous immune response to the AON.

28 April 2017 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
JCJoão Casaca-Carreira
João Casaca-Carreira
YTYasin Temel
Yasin Temel
SHSarah-Anna Hescham
Sarah-Anna Hescham
AJAli Jahanshahi
Ali Jahanshahi
Drug delivery to the central nervous system (CNS) is complicated by the blood-brain barrier. As a result, many agents that are found to be potentially effective at their site of action cannot be sufficiently or effectively delivered to the CNS and therefore have been discarded and not developed further for clinical use, leaving many CNS diseases untreated. One way to overcome this obstacle is intracerebroventricular (ICV) delivery of the therapeutics directly to cerebrospinal fluid (CSF). Recent experimental and clinical findings reveal that CSF flows from the ventricles throughout the parenchyma towards the subarachnoid space also named minor CSF pathway, while earlier, it was suggested that only in pathological conditions such as hydrocephalus this form of CSF flow occurs. This transependymal flow of CSF provides a route to distribute ICV-infused drugs throughout the brain. More insight on transependymal CSF flow will direct more rational to ICV drug delivery and broaden its clinical indications in managing CNS diseases.

7 September 2013
Verified
Book Chapter
Closed access
PDF file
JCJoão Casaca Carreira
João Casaca Carreira
AJAli Jahanshahi
Ali Jahanshahi
DZDagmar Zeef
Dagmar Zeef
EKErsoy Kocabicak
Ersoy Kocabicak
RVRinske Vlamings
Rinske Vlamings
YTYasin Temel
Yasin Temel

1 December 2016 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
JCJoão Casaca-Carreira
João Casaca-Carreira
LTLodewijk J.A. Toonen
Lodewijk J.A. Toonen
MEMelvin M. Evers
Melvin M. Evers
AJAli Jahanshahi
Ali Jahanshahi
WVWilleke M.C. Van-Roon-Mom
Willeke M.C. Van-Roon-Mom
Yasin TemelYasin Temel
Yasin Temel

18 October 2016 in Nucleic Acid Therapeutics
Verified
Journal Article
Closed access
JCJoão Casaca-Carreira
João Casaca-Carreira
YTYasin Temel
Yasin Temel
ILIñaki Larrakoetxea
Iñaki Larrakoetxea
AJAli Jahanshahi
Ali Jahanshahi
Antisense oligonucleotide (AON) therapy is emerging as a potential treatment strategy for neurodegenerative diseases, such as spinal muscular atrophy, Huntington's disease, and amyotrophic lateral sclerosis. AONs function at the cellular level by, for example, direct interference with the expression of gene products or the molecular activation of neuroprotective pathways. However, AON therapy faces a major obstacle limiting its clinical application for central nervous system (CNS) disorders: the blood–brain barrier. Systemic administration of AONs leads to rapid clearance and breakdown of its molecules in the periphery. One way to overcome this obstacle is intracerebroventricular (ICV) delivery of the therapeutics directly to cerebrospinal fluid (CSF). Given the particular molecular structure of oligonucleotides, the (pharmaco) kinetic and distribution pattern of these compounds in the brain are yet to be clarified. In this study, 2′OMePS oligonucleotide delivered through ICV into CSF reached the most key structures in the brain. The distribution of this oligonucleotide differed when comparing specific brain structures and cell groups. After 48 h post-infusion, the distribution of the oligonucleotide reached its maximum and was found intracellularly in many key brain structures. These findings help understanding the kinetic and distribution pattern of 2′OMePS oligonucleotide in the brain and will direct more rational and effective use of ICV drug delivery and unleash its full therapeutic potential in managing CNS diseases.

1 September 2014 in Journal of Chemical Neuroanatomy
Verified
Journal Article
Closed access
SHSarah Hescham
Sarah Hescham
YTYasin Temel
Yasin Temel
JCJoão Casaca-Carreira
João Casaca-Carreira
KAKemal Arslantas
Kemal Arslantas
YYYoussef Yakkioui
Youssef Yakkioui
AJAli Jahanshahi
Ali Jahanshahi